Business

Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply

Financial Post · September 23, 2026 at 9:04 a.m.

One cGMP batch, manufactured in-house under Optimi’s Health Canada Drug Establishment Licence, supplies both the Canadian trial and Australian clinics VANCOUVER, British Columbia, Sept.

23, 2026 (GLOBE NEWSWIRE) — Optimi

Read the full article on Financial Post ›

5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.

Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply

More from Financial Post

Cambria Gold Mines Intersects 98.56 g/t Gold over 8.2 Metres at the Silver Coin Deposit, Premier Gold Project

DCO Launches Second Edition of Digital Prosperity Awards to Recognize Solutions Building the Digital Future

Royal Canadian Legion statement: CFB Wainwright tragedy

The Plastic Surgery Foundation appoints Sara R. Dickie, MD, as President

More in Business

Cambria Gold Mines Intersects 98.56 g/t Gold over 8.2 Metres at the Silver Coin Deposit, Premier Gold Project

DCO Launches Second Edition of Digital Prosperity Awards to Recognize Solutions Building the Digital Future

Royal Canadian Legion statement: CFB Wainwright tragedy

The Plastic Surgery Foundation appoints Sara R. Dickie, MD, as President

Lynn A. Damitz, MD, FACS, named President of the American Society of Plastic Surgeons

Historic $250 Million Gift from John Paulson to Hebrew University Will Advance Engineering, Medicine, and Trauma Recovery